# Neo-DIANA: Neoadjuvant Treatment for EGFR Mutated Patients

> **NCT04512430** · PHASE2 · TERMINATED · sponsor: **Fundación GECP** · enrollment: 4 (actual)

## Conditions studied

- Non Small Cell Lung Cancer
- EGFR Gene Mutation

## Interventions

- **DRUG:** Atezolizumab
- **DRUG:** Bevacizumab
- **DRUG:** Carboplatin
- **DRUG:** Pemetrexed

## Key facts

- **NCT ID:** NCT04512430
- **Lead sponsor:** Fundación GECP
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-12-02
- **Primary completion:** 2024-07-19
- **Final completion:** 2024-07-19
- **Target enrollment:** 4 (ACTUAL)
- **Why stopped:** Low recruitment
- **Last updated:** 2025-04-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04512430

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04512430, "Neo-DIANA: Neoadjuvant Treatment for EGFR Mutated Patients". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT04512430. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*